ArticleCureus2026
Major Discordance in Hemoglobin A1c Measurement in Sickle Cell Trait: Effect of Analytical Methods.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Glycemic assessment when hemoglobin A1c is unreliable: a clinical-laboratory framework for kidney disease, anemia, and hemoglobinopathies.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemoglobin A1c (HbA1c) is widely used for diagnosing and monitoring diabetes mellitus and reflects long-term glycemic control. However, hemoglobin variants may interfere with certain assay methods, leading to misleading results. We report the case of a 54-year-old woman with sickle cell trait and long-standing diabetes who presented with markedly discordant HbA1c values obtained using two different methods. High-performance liquid chromatography (HPLC) showed a significantly elevated HbA1c level, whereas a fluorescence immunoassay yielded a substantially lower value, despite persistently elevated fasting plasma glucose and normal hematologic parameters. Hemoglobin electrophoresis confirmed sickle cell trait. Fructosamine levels were consistent with recent hyperglycemia. This case highlights the potential for hemoglobin variants to interfere with specific HbA1c assay techniques, resulting in inaccurate assessment of glycemic control. Clinicians should interpret HbA1c results cautiously in patients with known or suspected hemoglobin variants and consider alternative markers, such as fructosamine, to guide diabetes management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.